Biopharmaceutical services provider Parexel has formed a strategic collaboration with the Society for Clinical Research Sites (SCRS), an organisation focused on representing clinical research site interests.

Under the collaboration, Parexel will participate as a site engagement partner to enhance connections between sites and the industry to boost the clinical trial experience for patients.

The Global Site Solutions team of Parexel maintains a site alliance network of over 500 sites and 17,100 investigators worldwide.

Parexel executive vice-president Gadi Saarony said: “In clinical development, patient engagement is critical to success and investigative sites play an important role in enhancing engagement with patients.

“Parexel shares SCRS’ commitment to alignment among sites, patients and customers and is honoured to play an active role in driving key initiatives that ultimately will improve the experience for patients.”

As part of the partnership, Parexel and SCRS will work on initiatives, which will include Parexel leading a site advocacy group (SAG) on reducing patient burden in clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The biopharmaceutical services provider will join the SCRS Diversity Initiative to respond to clinical trial challenges and opportunities.

It will also explore the needs of diverse patient populations in clinical research participation worldwide.

SCRS president Casey Orvin said: “Our organisation has a longstanding track record of bringing together the key stakeholders involved in the drug development process to collaborate in new and different ways to address the toughest challenges in drug development.”